Deals of the Week: Sanofi/Selecta, Evotec/Probiodrug, Nestle/Chi-Med…
European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”
You may also be interested in...
Cancer drug developer Curis held its first R&D day Oct. 3, a sign its early pipeline is maturing. The company outlined development plans for two proprietary drugs, an IAP inhibitor and a PI3K/HDAC inhibitor, both in early clinical development. As for partnering those assets, CEO Passeri said the company is looking to retain more value for them than it did for Erivedge.
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.